This NMA is, to our knowledge, the first to consider all available comparative imaging data for PSMA and non-PSMA-based radiotracers in recurrent prostate cancers using a networked meta-analysis approach, confirmed by a search of the PROSPERO data-base, thus representing the most comprehensive review of available comparative radiotracer imaging trials for rPC. Here, FOLH1 is linked to prostate cancer.